Dr. Chengbin Wu, aged 57, is the founder of our Group. Dr. Wu was appointed as our Director on February 26, 2015. He was appointed as the chairman of our Board and chief executive officer on May 1, 2016 and was re-designated as our executive Director on May 28, 2025. Dr. Wu also served as (i) the director of EpimAb Shanghai since February 2016, the chief executive officer since May 2016 and chairman of the board since July 2017; (ii) the executive director and general manager of EpimAb Suzhou since January 2018; (iii) the executive director and manager of EpimAb Beijing since April 2021; and (iv) the director of EpimAb Holdings since November 2021. He is primarily responsible for providing the overall direction and leadership for our Group.
Dr. Wu possesses deep expertise in immunology and antibody research and biopharmaceutical development and has worked in different research institutes and pharmaceutical companies. Prior to founding of our Group, from August 1989 to August 1991, Dr. Wu was an instructor of the East China University of Science and Technology. Subsequently, he engaged in research activities in the field of immunology and antibody development at Harvard Medical School. From September 2002 to January 2010, he served as an associate research fellow at Abbott Laboratories, a leading global healthcare products company. From February 2010 to July 2013, he served as the vice president at Shanghai ChemPartner Co., Ltd. (now known as Shanghai ChemPartner Research Group Co., Ltd.), a scientific research outsourcing service organization. From August 2013 to April 2016, he served as the president of research and development and the chief science officer at Shanghai CP Guojian Pharmaceutical) (now known as Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.), a China-based biopharmaceutical company listed on the Shanghai Stock Exchange (stock code: 688336), where he was primarily responsible for leading the whole research and development department of the company.
Dr. Wu obtained his bachelor’s degree in biochemical engineering from the East China University of Science and Technology in the PRC in July 1989, his master’s degree of science from South Dakota State University in the United States in May 1993 and his Ph.D. degree in biochemistry and molecular biology from the University of Georgia in the United States in August 1997.
Dr. Stephen Lensky is our chief business officer and chief operating officer and is primarily responsible for managing the business development, IP, and portfolio strategy of our Group.
Dr. Lensky possesses more than 21 years of experience in pharmaceutical industry. Prior to joining our Group, in August 1993, Dr. Lensky joined Bayer AG, a chemical holding with pharmaceuticals business unit, where he worked at the international cooperation and licensing department and the business planning and administrations division from April 1999 to August 2003 and also assumed leadership of regional licensing Europe and overseas division in October 1999, where he was primarily responsible for managing regional and national licensing cooperation within European region, negotiating and overseeing negotiations of co-marketing and co-promotion agreements, as well as in- and out-licensing arrangements, product acquisitions and sales, along with potential contract amendments and terminations. He then worked at Boehringer Ingelheim GmbH, a healthcare holding with a pharmaceuticals business unit, where he was appointed as the licensing/contract manager of the corporate development division in September 2003 and the head of strategic transactions and alliance management in January 2010.
Dr. Lensky obtained the pre-diploma in chemistry from the University of Kiel in Germany in October 1986, and the diploma in chemistry and Ph.D. degree in organic chemistry from the University of Munich in Germany in August 1989 and April 1992, respectively.
Dr. Yonghong Zhu is our chief medical officer and is primarily responsible for overseeing the clinical pipeline and strategy and clinical organization of our Group.
Dr. Zhu brings over two decades of experience in clinical development, translational research, and drug discovery across multinational pharmaceutical and biotech companies. He previously served as the chief medical officer at MaxiNovel Pharmaceuticals Co., Ltd. from April 2021 to May 2023, where he was mainly responsible for clinical research and strategy. Before that, he also held positions in several biotech or pharmaceutical companies, including serving as a biomarker & experimental medicine leader at Roche Palo Alto LLC from December 2007 to December 2009, a senior clinical scientist and personalized healthcare leader at Genentech USA from January 2010 to May 2013, a senior medical director at Takeda Pharmaceuticals International, Inc. from May 2013 to January 2017, and the medical executive director at Shanghai Henlius Biotech Inc. from January 2017 to February 2018. Through these roles, he has developed deep expertise in therapeutic areas including oncology, immunology, and infectious diseases. Earlier in his career, Dr. Zhu focused on pre-clinical work at Sunesis Pharmaceuticals Inc. and Osel Inc. and also briefly practiced medicine from September 1994 to September 2007.
Dr. Zhu obtained his bachelor’s degree and his master’s degree in clinical medicine from Nanjing University in the PRC in July 1992 and July 1994, respectively. He obtained his Ph.D. degree in microbiology and immunology from the University of Rochester in the United States in May 2002, and completed the industrial postdoctoral training at DNAX Research Inc. (now part of Merck & Co., Inc.).
Dr. Xinyi Gu is our chief financial officer and is primarily responsible for leading the investor relations, finance and the procurement department of our Group.
Dr. Gu has over 16 years of extensive experience in the investment analysis and research pertaining to pharmaceutical and biotechnology industry. Prior to joining our Group, from September 2008 to April 2010, Dr. Gu served as a management consultant at McKinsey & Company, a consulting company, where he was mainly responsible for consulting for pharmaceutical companies. From June 2010 to June 2013, he served as an equity research associate at Wells Fargo Securities, an investment banking and capital market firm, where he was mainly responsible for analysis and recommendation of publicly listed generics and specialty pharmaceutical companies. From July 2013 to January 2018, he served as a research analyst at Jefferies LLC, an investment banking and capital market firm, where he was mainly responsible for analysis and recommendation of large-cap pharmaceuticals companies listed on the stock exchanges of the United States and the European Union. From January 2018 to February 2020, he served as a research analyst at Millennium Management LLC, a diversified alternative investment firm, where he was mainly responsible for analyzing accounting and financial statements, forecasting company financials and sales for key products, identifying financial strengths and weaknesses, and assessing near term and longer term strategic priorities for pharmaceutical and biotechnology companies.
Dr. Gu obtained his bachelor’s degree in biochemistry from the University of Illinois at Urbana-Champaign in the United States in May 2002 and his Ph.D. degree in pharmaceutical sciences from the University of Michigan —Ann Arbor in the United States in December 2008.
Ms. Qianmin Wu is the senior vice president of corporate finance and a joint company secretary of our Company and is primarily responsible for ensuring statutory and capital markets compliance, supporting corporate governance and Board operations, managing regulatory filing and disclosures and maintaining investor relationships.
Prior to joining our Group, from 2005 to 2008, she worked at Tianhe System Counsulting Services (Shanghai) Co., Ltd., a subsidiary of ZF TRW Automotive Holdings Corp. (formerly known as TRW Automotive Holdings), a company principally engaged in developing and manufacturing automotive parts. From December 2008 to July 2018, she worked as the finance director at GlaxoSmithKline (China) R$D Company Limited, a global pharmaceutical. From June 2018 to February 2022, she worked as the senior finance director for Brii China at Brii Bioscience (Beijing) Co., Ltd., a company listed on the Main Board of the Stock Exchange (stock code: 2137), where she was mainly responsible for finance matters in Brii Bioscience China. From March 2022 to March 2024, she worked as the vice president of finance at SanReno (Cayman) Therapeutics Co. Ltd, a biotech company focusing on kidney therapy, where she was mainly responsible for the overall management of finance. From April 2024 to April 2025, she worked as the senior vice president and head of finance at JW Therapeutics R&D Co., Ltd. where she was mainly responsible for the overall management of finance.
Ms. Wu obtained her bachelor’s degree in international trade from Shanghai University of Finance and Economics in the PRC in June 1999 and a master of business administration degree from Carleton University in Canada in November 2013. Ms. Wu obtained the certificate of internal audit issued by the Institute of Internal Auditors in November 2007.
